10326 results
W7.3 How can innovation in regulatory science inform the regulatory process to facilitate the development of new vaccines?
Marion Gruber
Workshop presentation
PresentationResearchEnglish
W7.2 Enhancement in Laboratory Research to Support Innovations in Regulatory Science for the Evaluation of New Vaccines
Teeranart Jivapaisarnpong
Workshop presentation
PresentationResearchEnglish
W7.1 Contributions of Regulatory Science to Vaccine Access
Norman W. Baylor
Workshop presentation
PresentationResearchEnglish
W6.3 Case Study: The Uniject Injection System
Debra Kristensen
Workshop presentation
PresentationUniJectResearchEnglish
W6.2 Beyond the cold chain… Meningitis A conjugate vaccine in a controlled temperature chain: Experience from Benin
Olivier Ronveaux
Workshop presentation
PresentationMenAfriVacResearchEnglishMeningococcal meningitis
W6.1 WHO - Next-generation Vaccine Delivery Technology Meeting Summary
Darin Zehrung
Workshop presentation
PresentationResearchEnglish
W5.4 Building Implementation Research Capacity for Polio Eradication
Margaret Gyapong
Workshop presentation
PresentationResearchEnglish
W5.3 Strengthening national capacity for evidence-based immunization policy: the case of program costing in Honduras
Cara Bess Janusz
Workshop presentation
PresentationResearchEnglish
W5.2 Factors influencing community health volunteers in participating in health programs in Africa
Fadima YAYA BOCOUM
Workshop presentation
PresentationResearchEnglish
W5.1 Immunization implementation research priority setting
John Clemens
Workshop presentation
PresentationResearchEnglish
W4.2 Prioritizing the Research Agenda for Measles and Rubella
William Moss
Workshop presentation
PresentationResearchEnglishRubellaMeasles
W4.1 Progress, Challenges, and Lessons Learned in Achieving Measles and Rubella Goals
Thomas Cherian
Workshop presentation
PresentationResearchEnglishRubellaMeasles
W3.2 Pre-exposure rabies vaccination (PreP) in children of endemic countries
D. Briggs
Workshop presentation
PresentationResearchEnglishRabies
W3.1 Leishmania Vaccine Development: Progress and challenges in the context of other control strategies
Farrokh Modabber
Workshop presentation
PresentationResearchEnglish
W2.3 Group A streptococcal vaccines: Challenges and progress
Florian Schödel
Workshop presentation
PresentationResearchEnglish
W2.2 RSV Vaccine Development for Low and Middle Income Countries: Challenges and Progress
Claudio Lanata
Workshop presentation
PresentationResearchEnglish
W2.1 WHO Preferred Product Characteristics: Bridging Vaccine R&D with Public Health
Vasee Moorthy
Workshop presentation
PresentationResearchEnglish
W1.1 Towards the Development of a Universal Influenza Vaccine
David Spiro
Workshop presentation
PresentationResearchEnglishInfluenza
P7.1 Innovation for vaccines against poverty diseases: the need for new support mechanisms
Martin Friede
Plenary presentation
PresentationResearchEnglish
P6.2 Maternal Immunization: which impact on infant immunity?
Claire-Anne Siegrist
Plenary presentation
PresentationResearchEnglish
P6.1 Public Health Benefits of Maternal Immunization
Keith Klugman
Plenary presentation
PresentationResearchEnglish
P5.2 Influenza Vaccine Use in the Americas: Network for Evaluation of Influenza Vaccine Effectiveness REVELAC-1
Alba Maria Ropero-Alvarez
Plenary presentation
PresentationResearchEnglishInfluenza
P5.1 Immunization Registries in Latin America and the Caribbean
M. Carolina Danovaro
Plenary presentation
PresentationRegistriesResearchEnglish
P3.4 Evaluation of the Next Generation of Rotavirus Vaccines
Kathleen Neuzil
Plenary presentation
PresentationResearchEnglishRotavirus
P3.3 Developing Next Generation Rotavirus Vaccines: Prospects from the Pipeline to Address Remaining Public Health Needs
Mary K. Estes
Plenary presentation
PresentationResearchEnglishRotavirus
P3.2 Developing Country Vaccine Manufacturers - Access to Immunization
Umesh Parashar
Plenary presentation
PresentationResearchEnglish
P3.1 Developing next generation vaccines: Introduction
Kathleen Neuzil
Plenary presentation
PresentationResearchEnglish
P2.2 Regulatory Considerations for Determining Vaccine Efficacy
Marion Gruber
Plenary presentation
PresentationResearchEnglish
P2.1 Regulatory and public health challenges
Peter Smith
Plenary presentation
PresentationResearchEnglish
P1c.2 Progress towards the development of a malaria vaccine: discussion
Peter Smith
Plenary presentation
PresentationResearchEnglishMalaria
P1c.1 Progress towards the development of a malaria vaccine
Ashley Birkett
Plenary presentation
PresentationResearchEnglishMalaria
P1b.2 TB Vaccine Development: Challenges & Opportunities
Uli Fruth
Plenary presentation
PresentationResearchEnglishTuberculosis
P1b.1 Update on Tuberculosis Vaccines - 2014
Tom Evans
Plenary presentation
PresentationResearchEnglishTuberculosis
P1a.2 Progress towards the development of an HIV vaccine: Discussion
José Esparza
Plenary presentation
PresentationResearchEnglishHIV-AIDS
P1a.1 Status of HIV Vaccine Research & Development
Wayne Koff
Plenary presentation
PresentationResearchEnglishHIV-AIDS
KN3-1 The Importance of Innovation in Addressing Global Health Gaps in the Developing World
T. Mundel, Bill & Melinda Gates Foundation
Keynote Address
PresentationResearchEnglish
KN2.2 Perspectives on Vaccines and Poverty Reduction
T. Evans, World Bank
Keynote Address
PresentationResearchEnglish
KN2.1 WHO Director-General address to GVIRF
Margaret Chan
Keynote Address
PresentationResearchEnglish
KN1.4 What do we expect from the meeting?
José Esparza
Introduction to GVIRF
PresentationResearchEnglishGlobal Vaccine Action Plan (GVAP)
KN1.3 GVIRF Overview and Goals
Joachim Hombach
Introduction to GVIRF
PresentationResearchEnglishGlobal Vaccine Action Plan (GVAP)
W8 Systems Vaccinology
Chair Ingileif Jonsdottir (University Hospital of Iceland)
W. Hanekom (BMGF), E. Hanon (GSK), I. Jonsdottir (U. Hospital Iceland), D. Lewis (U. Surrey), P. Neels (consultant), B. Pulendran (Emory U.)
ReportResearchEnglish
W7 Contributions of Regulatory Science to Vaccine Access
Chairs Norman Baylor and Helen Rees
V. Ahonkhai, N. Baylor, M. Gruber, T. Jivapaisarnpong, H. Rees, D. Wood
ReportResearchEnglish
W6 Innovation in vaccine delivery and presentation: How can technological advances increase program performance?
Chairs M. Gottlieb and R. Lagos
M. Gottleib, D. Kristensen, R. Lagos, O. Popova, O. Ronveaux, D. Zehrung
ReportResearchEnglish
W4 How to Optimize Immunization Coverage? A case study from Measles-Rubella vaccination
Chair David Durrheim
T. Cherian, D. Durrheim, W. Moss, W. Orenstein, H. Rees
ReportResearchEnglishRubellaMeasles
W2 Preferred Product Characteristics (PPC) as a Way to Guide Development of Products of High Public Health Utility
Chair Gerd Zettlmeisl
David Kaslow, Rosanna Lagos, Claudio Lanata, Vasee Moorthy, Florian Schödel, Gerd Zettlmeissl
ReportResearchEnglish
W1 Towards the Development of a Universal Influenza Vaccine
Chair David Spiro (NIAID/NIH)
R. Donis (US CDC), R. Rappuoli (Novartis), G. Nabel (Sanofi), N. Baylor (Biologics Consulting), P. Palese (Mt. Sinai), H. Golding (US FDA)
ReportResearchEnglishInfluenza
W6.4 Second year of life platform and monitoring systems
Jan Grevendonk
Workshop presentation
PresentationResearchEnglishMeasles
W6.3 Protecting Lives in the 2nd Year of Life (2YL) in Ghana
Abigail Shefer
Workshop presentation
PresentationResearchEnglishMeasles
W6.2 Raising the Profile of an 18-month Well-child Visit: the 2YL Platform
Elicah Kandinda Kamiji
Workshop presentation
PresentationResearchEnglishMeasles
W6.1 Global landscape analysis and literature review of 2nd year of life immunization platform
Imran Mirza
Workshop presentation
PresentationResearchEnglishMeasles
W6.0 Intro: Establishing a Second-year-of-life (2YL) Healthy Child Visit
Rudi Eggers
Workshop presentation
PresentationResearchEnglishMeasles
W6 Immunization in the Second Year of Life
Chair Rebecca Fields
Rudi Eggers (WHO), Jan Grevendonk (WHO), Elicah Kandinda Kamiji (MoH Zambia), Imran Mirza (UNICEF), Abigail Shefer (US CDC)
ReportResearchEnglishMeasles
W5.3 Good Participatory Practices for Vaccine Clinical Trials
Nelson Michael
Workshop presentation
PresentationResearchEnglishHIV-AIDS
W5.2 African Vaccine Regulatory Forum (AVAREF): New Vision and Blueprint for Ethics and Regulatory Capacity Strengthening in Africa
Dicky Akanmori
Workshop presentation
PresentationResearchEnglish
W5.1 WHO Regulatory Strengthening Update & LMICs Challenges in Vaccine Clinical Trial Regulation
William Wekwete
Workshop presentation
PresentationResearchEnglish
W5 Regulatory Challenges and Constraints When Evaluating Vaccine Clinical Trials
Chair Klaus Cichutek
Dick Akanmori (WHO), Marco Cavaleri (EMA), Nelson Michael (MHRP/WRAIR), Nicholas Perombelom (IFPMA), Helen Rees (U. of Witwatersrand), William Wekwete (Medicines Control Agency of Zimbabwe)
ReportResearchEnglish
W4.6 Vaccines for healthcare pathogens: No ESKAPE
Jordi Rello
Workshop presentation
PresentationResearchEnglish
W4.5 Gonococcal antimicrobial resistance and vaccines
Magnus Unemo
Workshop presentation
PresentationResearchEnglish
W4.4 Vaccines to prevent antibiotic-resistant Staphylococcus aureus (MRSA) infections
Olaf Schneewind
Workshop presentation
PresentationResearchEnglish
W4.3 The Role of Vaccines in Antimicrobial Resistance Strategies
Bruce Gellin
Workshop presentation
PresentationResearchEnglish
W4.2 WHO Global Action Plan on Antimicrobial Resistance
Martin Friede
Workshop presentation
PresentationResearchEnglish
W4.1 Introduction: Antimicrobial Resistance & Vaccines
Chair Dennis M Dixon
Workshop presentation
PresentationResearchEnglish
W3.4 Vaccine technology costs and health impact assessment tool
Mercy Mvundura
Workshop presentation
PresentationResearchEnglish
W3.3 Microarray patch case study: Measles-rubella vaccine
Darin Zehrung
Workshop presentation
PresentationResearchEnglishRubellaMeasles
W3.2 Total System Effectiveness
Tina Lorenson
Workshop presentation
PresentationResearchEnglish
W3.1 Introduction: Total Systems Effectiveness
Tina Lorenson
Workshop presentation
PresentationResearchEnglish
W2.2 Public Health Criteria for Dengue Vaccine Risk/Benefit Assessment and Risk Management
Peter Smith
Workshop presentation
PresentationResearchEnglishDengue
W11.4 Applying TIP to low and middle income settings: a case study from South Africa
Nicola Christofides and Janine Simon-Meyer
Workshop presentation
PresentationVaccine hesitancyResearchEnglish
W11.3 Tailoring Immunization Programmes (TIP): An example of tailoring communication on vaccinations targeting hard.to.serve communities in Sweden
Ann Lindstrand
Workshop presentation
PresentationVaccine hesitancyEnglish
W11.2 Vaccine Hesitancy: Determining the scale of the challenge
Susan Goldstein
Workshop presentation
PresentationVaccine hesitancyResearchEnglish
W11.1 Vaccine Hesitancy: what it means and what we need to know in order to tackle it
Robb Butler
Workshop presentation
PresentationVaccine hesitancyResearchEnglish
W10.4 Rabies antibodies for Passive Post-exposure prophylaxis
Tsepo Tsekoa
Workshop presentation
PresentationResearchEnglishRabies
W10.3 Gene-based Delivery of Broadly Neutralizing Antibodies for HIV Prevention
Wayne Koff
Workshop presentation
PresentationResearchEnglishHIV-AIDS
W10.2 Passive vaccination as a global strategy for preventing RSV disease in infants
Filip Dubovsky
Workshop presentation
PresentationResearchEnglish
W10.1 Monoclonal antibodies for infectious diseases
Martin Friede
Workshop presentation
PresentationResearchEnglish
W1.3 Design of self-assembling protein nanomaterials as next.generation vaccine scaffolds
Neil King
Workshop presentation
PresentationResearchEnglish
W1.2 Epitope-focused vaccine design
Bill Schief
Workshop presentation
PresentationResearchEnglish
W1.1 Structural studies of viral envelope proteins and insights for vaccine design
Felix Rey
Workshop presentation
PresentationResearchEnglish
W1.0 Introduction: Applying Novel Technologies to Vaccine Development
Rino Rappuoli
Workshop presentation
PresentationResearchEnglish
W9.4 Antibody Engineering: Optimization of Antibodies for Commercialization
Stephen Hadley
Workshop presentation
PresentationResearchEnglish
W9.3 Monoclonal Antibodies for Influenza Prevention, Therapy, or Vaccine Antigen Design
Bruce Innis
Workshop presentation
PresentationResearchEnglishInfluenza
W9.2 Monoclonal antibodies for rabies post-exposure prophylaxis
Erin Sparrow
Workshop presentation
PresentationResearchEnglishRabies
W9.1 Pipeline of HIV monoclonal antibodies for prevention of HIV
Barney Graham
Workshop presentation
PresentationResearchEnglishHIV-AIDS
W8.3 The Principle and Process of Autogenous Vaccine
Suphot Wattanaphansak
Workshop presentation
PresentationResearchEnglish
W8.2 Vaccination against bacterial diseases in farmed Atlantic salmon: experience and global applicability
Edgar Brun
Workshop presentation
PresentationResearchEnglish
W8.1 Antimicrobial Resistance and Vaccines
Dennis Dixon
Workshop presentation
PresentationResearchEnglish
W7.5 Target Value Proposition
Jean Lang
Workshop presentation
PresentationResearchEnglish
W7.4 Human Hookworm Vaccine Initiative: a Public Health value proposition leading to societal impact and positive financial returns
Maria Elena Bottazzi
Workshop presentation
PresentationResearchEnglish
W7.3 A Hepatitis C Virus Vaccine Update
Andrea Cox
Workshop presentation
PresentationResearchEnglish
W7.2 Update on RSV Vaccine and mAb development
Ruth Karron
Workshop presentation
PresentationResearchEnglish
W7.1 Global Vaccine Pipeline and Value Proposition
David Kaslow
Workshop presentation
PresentationResearchEnglish
W6.3 Maternal and adolescents immunization - a global challenge
Raymond Hutubessy
Workshop presentation
PresentationResearchEnglish
W6.2 Adolescent Immunization in Developing Countries: Obstacles and Opportunities
Hartono Gunardi
Workshop presentation
PresentationHPVResearchEnglishHuman papillomavirus
Qualification of temperature-controlled storage
Nathan Roman - 2022
WHO Technical Report Series, No. 961, 2011 Document below... Document attached to this post is the technical supplement 7: Qualification of temperature-controlled storage areas. Experts on the...
Forum post Temperature monitoring Cold room / freezer room
W9 Gavi's Vaccine Investment Strategy (VIS)
Chair Helen Rees
Bernadette Abela Ridder (WHO), Seth Berkley (Gavi), Katherind O'Brien (Johns Hopkins U.), Saad Omer (Emory U.)
ReportResearchEnglish
W8 Combination Vaccines: Why and How?
Chair Ralf Clemens
Michel de Wilde (consultant), Peter Dull (BMGF), Melissa Malhame (Gavi)
ReportResearchEnglish
W2 Comprehensive assessment of risks and benefits of vaccines: the example of Dengue
Chairs Lucky Slamet and Stephen Thomas
Stephen Thomas (WRAIR), Peter Smith (LSHTM), Gandi Rayón Ramírez (COFEPRIS), Chris Nelson (Sanofi Pasteur) Kwasi Amfo (Takeda), Alex Precioso (Butantan), Hasitha Tissera (Sri Lanka MOH)
ReportResearchEnglishDengue
P6.4 Preferred Product Characteristics
David Kaslow, PATH
Plenary presentation
PresentationResearchEnglish
P6.3 Schistosomiasis Vaccine Updates
Annie Mo
Plenary presentation
PresentationEnglish